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submissions, in 53% of cases a high ICER was reported in the summary of guidance 
as a reason for rejection. In about 30% of these cases, the high drug cost was speciﬁ ed 
as the driver of the high ICER. The lack of a robust economic case was mentioned in 
45% of rejections. Limited evidence of clinical beneﬁ t was shown in 43% of cases. 
Other reasons included inadequate type or quality of clinical data (21%) and non-
acceptance of clinical positioning (11%). In 45% of cases the rejections were largely 
due to economic reasons; 6% of cases were not accepted due primarily to clinical 
reasons and in 49% of rejections the criticisms related to both the economic and 
clinical evidence. Uncertainty in the evidence was reported as a problem in most nega-
tive recommendations. CONCLUSIONS: Only slightly over half of the orphan drug 
HTA submissions to these agencies are explicitly rejected primarily on the basis of a 
high ICER. Most HTA rejections are due to a combined lack of robust economic and 
clinical evidence. This suggests that collecting the right kind of data and presenting a 
solid case that accounts adequately for any uncertainty is at least as important as 
meeting trial endpoints and choosing an optimal price.
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OBJECTIVES: Orphan drugs (ODs) face numerous difﬁ culties in demonstrating their 
value through rigorous HTA processes. HTA bodies may therefore choose to take into 
consideration the special circumstances of treatments for orphan indications, either 
formally or informally. The objective of this study was to examine the decisions made 
on ODs by six English-speaking HTA bodies, and assess potential trends between 
agencies. METHODS: AWMSG, CEDAC, NCPE, NICE, PBAC and SMC HTA web-
sites were searched for completed OD assessments (identiﬁ ed via Orphanet website) 
as of April 2010, and data extracted on the recommendations. Recommendations with 
restrictions were categorised as approvals. Comparisons were made to published 
approval rates for drug submissions as a whole. RESULTS: Of the 71 ODs selected, 
55 were assessed by at least one HTA body. The proportion of positive recommenda-
tions for orphan treatments was lower than published approval rates for general 
(orphan and non-orphan) HTA drug submissions in most bodies. NICE approved 
67% completed OD submissions, versus approximately 87% of drugs overall. 
However, PBAC recommended 60% of ODs compared to 54% of drugs as a whole. 
Decisions also varied substantially between agencies. CEDAC had the highest propor-
tion of rejections (73%), compared to NICE, which rejected 33%. There was also 
variation in decisions made on speciﬁ c treatments. Sutent, for example, with an orphan 
designation for renal cell carcinoma, was accepted by AWMSG, CEDAC and SMC, 
while it received a negative recommendation from NCPE, NICE and PBAC. CON-
CLUSIONS: The willingness to assess ODs varies widely by agency and drug, as do 
resultant approval rates. HTA agencies are far more likely to reject OD submissions 
than non-orphan drugs as a whole. However given the differences in their remit to 
assess ODs, direct comparisons should be interpreted with caution. Further research 
is needed to explore the reasons behind these differences in HTA agency decisions.
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OBJECTIVES: To describe research methods and key issues in the HTA process in 
Europe. METHODS: Representatives from HTA bodies globally were recruited by 
members of the ISPOR HTA SIG Research Methods/Principles Working Group to 
complete a 45-minute on-line survey consisting of 48 items within 4 topics related to 
1) organizational information and process; 2) primary HTA methodologies and impor-
tance of attributes; 3) HTA application and dissemination; and 4) quality of HTA 
including key issues. Data were reported for Europe. RESULTS: The survey was 
completed by 11 European countries including Austria, Denmark, France, Germany, 
Hungary, Italy, The Netherlands, Portugal, Spain, Sweden, and Switzerland. Top 
reasons technologies were evaluated included perceived impact on patient outcomes, 
potential cost, and prevalence of the condition. The most common methodologies used 
were cost/economic analyses, systematic reviews & meta-analyses, clinical trials, mod-
eling, and comparative analyses. The most important attributes (in order) were effec-
tiveness, efﬁ cacy, safety, cost-effectiveness, and budget impact. While quality of life 
was frequently assessed by >74% of European respondents, it was not listed as an 
attribute of top importance. Only 24% repeat/update the assessment at regular inter-
vals. For 82% a different organization makes the ﬁ nal decision on coverage, only 
partially relying on the report. The most common educational background for decision 
makers was physician-specialist. Stakeholders are allowed to review the report and 
are involved in assessments >50% of the time, and in the ﬁ nal decisions ~35% of the 
time. Key issues/trends included early assessment of technologies with mechanism for 
conditional coverage, increasing regional interest in HTA, reassessment/horizon scan-
ning, and link between theory and practice in HTA. CONCLUSIONS: This survey of 
representatives within HTA and reimbursement bodies provides current insight into 
the state of HTA research methods in Europe. Future research could expand the results 
to speciﬁ cally address Eastern European countries, Asia, and other emerging markets.
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OBJECTIVES: To assess the outcomes of NICE’s guidance in totality and different 
disease areas. METHODS: A list of NICE Guidance published between 2007 to the 
end of 2009 was identiﬁ ed using HTAinSite™. We classiﬁ ed these recommendations 
into; ‘recommended’, ‘restricted’ and ‘not recommended’, and calculated the percent-
ages. We then analyzed these recommendations according to disease areas; ‘cardio-
vascular/metabolics’, ‘mental health’, ‘infectious diseases’, muscoskeletal conditions’, 
‘oncology’, and ‘others’. RESULTS: In 2007, NICE assessed 25 drugs, 31 in 2008 and 
18 in 2009. Of these, in 2007 NICE recommended 8 drugs (31%) for all eligible 
patients, restricted 13 (53%), and did not recommend 4 (16%). In 2008, 3 (10%) 
were recommended, 21 (68%) were restricted, and 7 (22%) were not recommended. 
Finally, in 2009, 2 (11%) treatments were recommended, while 11 (61%) received 
restricted recommendations and 5 (28%) were not recommended. Between 2007 and 
2009 NICE completed 7 appraisals in ‘cardiovascular/metabolics’ of which 4 received 
a full recommendation, while in ‘mental health’ 2 out of 2 were fully recommended. 
In contrast, in ‘infectious diseases’, 1 out of 5 was fully recommended. In ‘muscoskel-
etal conditions’ only 1 out of 21 were recommended (17 restricted and 3 not recom-
mended) while in ‘oncology’ only 1 out of 23 received a full recommendation (13 
restricted, 9 not recommended). In the ‘others’ group, 4 out of 12 received a recom-
mendation (6 restricted, 2 not recommended). If manufacturers had not proposed 
Patient Access Schemes (PAS) the proportion of guidance not recommended in 2009 
would be 44%. CONCLUSIONS: Appraisal outcomes have become more restrictive 
over time. Furthermore, low cost primary care therapeutics are more likely to receive 
a positive NICE recommendation than high cost speciality care interventions. 
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OBJECTIVES: Over the last decade the National Institute of Clinical Excellence in 
the UK has published guidelines for health technology assessments (HTA) that includes 
recommendations on health outcomes and cost-effectiveness assessments. In Europe, 
this has opened the opportunity for countries to either propose their own guidelines 
or use the British ones. The ECHOUTCOME project is an interdisciplinary European 
research platform funded by the seventh Framework Program of the European Com-
mission with the aim of designing new European guidelines in Health Outcomes and 
Cost-Effectiveness assessments. METHODS: This three years project is structured in 
three phases. Phase 1 aims to conduct a pan-European survey of HTA organizations 
and health outcomes use in the 27 European countries. Multiple correspondence and 
cluster analyses will be carried out to study the potential similarities and divergences 
across Europe. The objective of Phase 2 is to test the robustness and underlying 
assumptions such as reproducibility, neutrality to risk, constancy of time-trade-off 
rate, utility independence, etc. on QALYs, DALYs and HYEs measures. This testing 
will be conducted in the general population (n = 300 per country) in Belgium, France, 
Italy and UK. Phase 3 aims to propose new approaches in Health Outcomes and 
Cost-Effectiveness analyses. RESULTS: The main deliverable of the ECHOUTCOME 
project will be new European Guidelines for assessing Health Outcomes and conduct-
ing Cost-Effectiveness assessments. Of particular interest will be the recommendations 
on the practical usefulness of QALYs, DALYs and HYEs based on the experimental 
validation of their underlying assumptions. CONCLUSIONS: The ECHOUTCOME 
project is the ﬁ rst European validation study of health outcomes measures. This work 
will produce guidelines for public health decision-making in the 27 European 
countries. The ECHOUTCOME outcomes will enhance the debate and increase the 
understanding that will improve the knowledge of existing Health Outcomes 
and Cost-Effectiveness techniques and will promote new approaches for 
decision-making.
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OBJECTIVES: The popularity and availability of biomarkers has rapidly increased in 
recent years, thanks to innovative advances in pharmacogenomics. Predictive biomarkers 
have high potential value in HTA as they may increase the observed efﬁ cacy and cost-
effectiveness of treatments. This study reviews, in selected major markets worldwide, 
the impact of currently available predictive biomarkers on HTA in the context of the 
agency’s evidence requirements. METHODS: A broad review of biomarker tests used 
in HTA submissions in Europe, Australia, Canada, and the US was conducted; the 
A424 13th Euro Abstracts
outcome of the HTA recorded and the impact of the biomarker test on the submission 
outcome was graded as high, medium or low according to its inﬂ uence on the ﬁ nal 
decision. These ﬁ ndings were summarised, and 6 drugs were selected as case studies in 
order to identify key lessons relating to the risks, consequences, and ethical consider-
ations of Diagnostic/Treatment partnering. RESULTS: The review identiﬁ ed ﬁ ve bio-
markers in the ﬁ ve treatment areas of: HIV, Gastrointestinal stromal tumour (GIST), 
Non-small cell lung cancer (NSCLC), Colorectal cancer (CRC), and Breast cancer. 
Markers Her2 and K-RAS had a high impact in all included submissions, with 100% 
and 63% of these submissions resulting in a positive recommendation. In contrast, 
marker EGFR had a lower impact (not mentioned in 4 out of 10 submissions), with 
60% of these submissions being approved, and 40% rejected. The agencies most likely 
to reject a surrogate-outcome submission were PBAC (Australia) and SMC (Scotland) 
with rejection rates of 57% and 66% respectively, whereas CADTH accepted 100% of 
included submissions. CONCLUSIONS: Findings indicate ﬁ rstly that substantially dif-
ferent evidence requirements exist between HTA bodies in the markets considered (e.g. 
differing accuracy acceptability thresholds, prospective/retrospective analysis and the 
importance of cost-effectiveness), and secondly there are several ethical considerations 
to the selection or deselection of patients for treatment.
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OBJECTIVES: HTAinSite is an on-line, subscription-based database of all NICE 
Technology Appraisals (TAs). It includes information relating to submitted evidence, 
appraisal process and ﬁ nal decision and enables assessment of associated trends. 
METHODS: An academic steering group designed and agreed the data extraction 
protocol. a team of reviewers conducted the initial data extraction, which was vali-
dated by a second reviewer. Historical extraction is complete, with on-going TAs 
extracted on a monthly basis. RESULTS: A total of 181 TAs have been extracted to 
date, 5 of which were terminated, resulting in 176 complete TAs relating to 326 tech-
nologies. Of these, 53% were awarded a restricted decision, 32% were fully recom-
mended and 16% rejected. Of the three most commonly appraised disease areas (cancer, 
cardiovascular (CVS), central nervous system (CNS); CVS technologies were least com-
monly rejected by NICE (3% vs. 21% for cancer and 17% for CNS). Of the four most 
commonly used assessment groups (Shefﬁ eld, York, Southampton and Birmingham); 
technologies assessed by Shefﬁ eld were most commonly rejected (28%) and those by 
York were least commonly rejected (4%). Technologies supported by a patient submis-
sion were less commonly rejected than those without (15% vs. 29%). a total of 35 TAs 
(20%) resulted in an appeal, no appeals were upheld entirely, all appeals were upheld 
partially. HTAinSite also allows detailed analysis of individual TAs and cross-compar-
ison between TAs as well as identifying trends between submitted evidence (acquisition 
costs, budget impact, cost-effectiveness and clinical effectiveness) and ﬁ nal outcome. 
These additional analyses will be further explored in the poster and preliminary results 
will also be updated. CONCLUSIONS: HTAinSite is a useful tool for anyone interested 
in understanding the relationship between submitted evidence and ultimate NICE 
decision. The HTAinSite format may be useful for other HTA bodies, depending on 
the public availability of relevant information.
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OBJECTIVES: Mathematical models are required by decision makers to provide 
insight into pharmcoeconomic beneﬁ ts associated with a product. It is therefore 
essential that manufacturers understand economic evidence requirements when sub-
mitting an application to a Health Technology Assessment (HTA) agency. METHODS: 
A literature search of economic recommendations from the following HTA agencies 
was conducted: CADTH (Canada), HAS (France), IQWiG (Germany), NICE 
(England), PBAC (Australia), PHARMAC (New Zealand) and SMC (Scotland). 
RESULTS: Cost-effectiveness analysis is considered the most relevant analytical tech-
nique across the English-speaking agencies with a preference for QALY-based analysis, 
in contrast to IQWiG which does not consider QALYs and utilities as central to their 
methods. Unlike other HTA agencies assessed, the French agency HAS does not cur-
rently require cost-effectiveness modelling in its decision-making process. EQ-5D is 
the most commonly used utility instrument, NICE being the most prescriptive agency 
in this regard. However, utilities mapped from disease-speciﬁ c quality of life measures 
may be accepted and agencies such as PBAC and IQWiG express no formal preference 
between instruments. The third-party payer is the most commonly required perspective 
adopted across the English-speaking agencies while IQWiG and PBAC recommend a 
societal perspective in addition to the payer’s perspective. This trend towards a 
broader, societal perspective may, however, be limited by uncertainties around mea-
surement of wider costs. Sensitivity analyses are required by all agencies to explore 
uncertainty in the model. NICE and CADTH both favor a probabilistic approach 
while PBAC prefers univariate and multivariate analyses. Other agencies expect the 
manufacturer to justify their approach and choice. CONCLUSIONS: The recommen-
dations of IQWiG and PBAC differ from the other selected agencies. Uniquely, in 
France the pharmaeconomic case is considered separately from the HTA process by 
the French Health Economists Association. These differences between agencies should 
be considered when planning evidence generation activities to support economic model 
development.
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OBJECTIVES: Health Technology Assessment (HTA) agencies require various types 
and qualities of evidence for clinical effectiveness evaluations due to differences in 
health care systems and policies. It is essential for manufacturers to understand these 
requirements when submitting an application to each individual HTA agency. 
METHODS: A literature search of clinical recommendations from the following HTA 
agencies was conducted for comparison: CADTH (Canada), HAS (France), IQWiG 
(Germany), NICE (England), PBAC (Australia), PHARMAC (New Zealand) and SMC 
(Scotland). RESULTS: The choice of the optimal comparator is crucial to the outcome 
of the HTA. Almost all agencies prefer comparison versus the most frequently used 
interventions except for PBAC which requires comparison to the interventions most 
likely to be displaced. All HTA agencies are cautious in their interpretation of sur-
rogate outcomes (SO) and require manufacturers to provide evidence linking the SO 
to ﬁ nal patient-relevant outcomes. PBAC has notably developed a framework for 
assessing SOs and the impact of these on uncertainty in HTA submissions. Most 
agencies except for NICE clearly state their position on the deﬁ nition and the use of 
SOs. All agencies recognize the value of observational studies in reﬂ ecting real-world 
situations and providing long-term data although RCTs provide the key evidence on 
comparative effectiveness. Systematic reviews (SR) of clinical evidence are essential to 
present comparative effectiveness relative to all comparators. Contrary to most agen-
cies, HAS prefers SRs but does not require them and bases its assessments mainly on 
pivotal clinical trials provided by the manufacturer. NICE and IQWiG also differ from 
the other agencies as they perform in-house SR in addition to the manufacturer’s. 
CONCLUSIONS: The differences between agency requirements are subtle and mean 
that manufacturers need to put together a solid clinical evidence package needing very 
little adaptation to meet the seven country requirements.
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OBJECTIVES: The EUnetHTA Joint Action (2010–2012) is a joint initiative by EU 
Member States and the European Commission to advance European collaboration on 
health technology assessment (HTA). Part of the EUnetHTA Joint Action aims at 
reviewing methods used for the relative effectiveness assessment (REA) of pharmaceu-
ticals and to develop, apply and ﬁ eld-test tools and methods. As a ﬁ rst step towards 
this goal, objectives, processes and methodologies used for REA by HTA organizations 
across Europe and other countries are summarised. This overview is crucial for the 
development of shared or common methodologies to be used in future REA across 
Europe. METHODS: Data were captured with a standardised data abstraction form. 
Data were initially abstracted from different types of literature (peer reviewed, grey 
literature, EU and national reports etc.). Where there were gaps in the data, telephone 
interviews were arranged with a relevant person at the respective HTA or reimburse-
ment agency. RESULTS: Most European countries carry out some form of REA, 
however the deﬁ nitions of the assessments in general are not consistent with the deﬁ ni-
tion by the Pharmaceutical Forum. In addition the scope (inclusions of beneﬁ t-risk 
analysis and/or a cost-effectiveness analysis), the process (timing, involvement of 
stakeholders and separation of assessment and appraisal phase) and the purpose 
(inform clinical decision-making, reimbursement and/or for pricing decision-making) 
of the assessments vary as well as the methods (such as inclusion of surrogate end-
points, composite endpoints and quality of life data and extrapolation of efﬁ cacy 
data). Most agencies publish a guideline for the methodology used for REA however 
few publish them in English. CONCLUSIONS: A considerable number of European 
countries carry out REAs. However, the purpose and the methodology used vary 
across Europe. The reasons behind these differences need to be considered in the 
development of a common European methodology for REA. 
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OBJECTIVES: To identify the pharmaceutical and medical innovations that contributed 
mostly to the improvement of Greek population health status during the last three 
decades, according to physicians’ views. METHODS: Building on the methodology by 
Fuchs and Sox, a questionnaire based survey was conducted on a representative sample 
of 500 Greek internists and general practitioners aged ≥50 years old. The study question-
naire was formulated by a panel of experts, with the use of the Delphi method and 
included one list of 22 pharmaceutical and a second list of 20 medical innovations. 
Physicians were asked to identify the seven more important and seven least important 
